Development of a new generation of drugs (Protacs).
This is an already active project to create new Protacs drugs (a type of precision drug, more efficient than classic drugs) for human pathologies, aimed at the therapeutic target IMPDH (therapeutic targets are the place in the body where the drug performs its action). This target is very relevant in carcinogenic processes. IMPDH is also a very important target in viral processes, and its chemical inhibition by specific drugs (compounds that block the spread of SARS-CoV-2) has already been described as a plausible strategy against the coronavirus.
Principal Investigator: Bernat Crosas (IBMB)